Download Image
    
Share
  
Post
Tradipitant for COVID-19
1 study with 145 patients
Hospital Icon Control
Hospital Icon Tradipitant Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Tradipitant studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -36% Mortality -36% RCTs -36% Late -36% Favorstradipitant Favorscontrol
Tradipitant is an oral small-molecule neurokinin-1 receptor antagonist that blocks substance P signalling, potentially reducing neurogenic pulmonary inflammation.
Apr 1
2024
 Polymeropoulos et al., NCT04326426 ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection
36% higher mortality (p=0.41) and no change in improvement. RCT 145 severe/critical COVID-19 patients in the USA, showing no significant difference with tradipitant treatment.